F-star Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.11.22	F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research (GlobeNewswire)
11.08.22	F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
20.07.22	F-star Therapeutics Inks License Deal With Takeda To Develop Bispecific Antibody (RTTNews)
20.07.22	F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody (GlobeNewswire)
18.07.22	INVESTIGATION ALERT: Halper Sadeh LLP Investigates PCSB, STCN, USWS, FSTX (PR Newswire)
11.07.22	INVESTIGATION NOTICE: Halper Sadeh LLP Investigates DRE, RDUS, FSTX, RADA, USAK (PR Newswire)
27.06.22	INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, FSTX, ZEN, USAK (PR Newswire)
23.06.22	invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs (GlobeNewswire)
10.05.22	F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
02.05.22	F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022 (GlobeNewswire)
08.04.22	F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022 (GlobeNewswire)
14.03.22	F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
10.03.22	F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire)
02.03.22	F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022 (GlobeNewswire)
01.03.22	F-star Therapeutics Appoints James Sandy as Chief Development Officer (GlobeNewswire)
20.01.22	F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3 (GlobeNewswire)
07.01.22	F-star Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
05.01.22	F-star Therapeutics : Merck KGaA Exercises Fourth Licensing Option In Immuno-Oncology Collaboration (RTTNews)
05.01.22	F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration (GlobeNewswire)
07.12.21	F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021 (GlobeNewswire)
29.11.21	F-star Therapeutics to Host Virtual R&D Day on December 6, 2021 (GlobeNewswire)
12.11.21	F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference (GlobeNewswire)
10.11.21	F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
01.11.21	F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021 (GlobeNewswire)
20.10.21	F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics (GlobeNewswire)
16.09.21	F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021 (GlobeNewswire)
09.09.21	F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
01.09.21	Will The Trials Of Bispecific Antibodies Add Shine To F-star Therapeutics? (RTTNews)
12.08.21	F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
10.08.21	F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285 (GlobeNewswire)
04.08.21	F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA (GlobeNewswire)
02.08.21	F-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021 (GlobeNewswire)
26.07.21	F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors (GlobeNewswire)
09.07.21	F-star Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
08.07.21	F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors (GlobeNewswire)
17.05.21	F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
10.05.21	F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021 (GlobeNewswire)
07.05.21	F-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common Stock (GlobeNewswire)
06.05.21	F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
19.04.21	Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy (GlobeNewswire)
10.04.21	F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster (GlobeNewswire)
01.04.21	F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration (GlobeNewswire)
29.03.21	F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
04.03.21	F-star Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
20.01.21	F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1 (GlobeNewswire)
06.01.21	F-star Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
04.01.21	F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu F-star Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten